An active pharmaceutical ingredient (API) is the substance in a medicine that produces its intended effect. Teva’s API business, known as TAPI, develops and manufactures small-molecule ingredients for generic and innovative drugs and supplies pharmaceutical and biotechnology customers, including Teva.
Ingredients are distinct from finished medicines
An API is not a finished tablet, capsule or injection. It is the active chemical component incorporated into a dosage form, which must also meet applicable quality and regulatory requirements. In its January 2024 announcement, Teva described TAPI as serving more than 1,000 customers worldwide with a portfolio of 350 products.
Ingredient production connects chemical manufacturing to finished medicines used by patients. Pharmaceutical companies may make their own APIs or source them from specialist suppliers. A customer that purchases an ingredient remains responsible for ensuring the finished product meets the requirements of the markets where it is sold. Israel’s Ministry of Health describes its GMP inspection remit for active ingredients and medicines in its pharmaceutical standards and quality control unit.
Teva announced a plan, not a completed sale
On January 31, 2024, Teva announced its intention to divest TAPI as part of its Pivot to Growth strategy. The company said it expected a potential transaction to close in the first half of 2025, subject to an agreement and closing conditions, and stated that there was no assurance a deal would be reached or completed. The announcement sets out the proposed timing and makes clear that it was a plan.
Teva’s 2024 Form 10-K reported that the company classified the API business, including research, manufacturing and commercial activities, as held for sale on December 31, 2024. That accounting classification records an intended transaction; it does not mean the sale had closed. The 2024 annual filing also notes that completion remained uncertain. For Teva’s broader growth through acquisitions, see its international expansion.